Clinical Trial Update: Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients - A Three Year Extension

View source ↗

Summary

A three-year extension study evaluating cognitive outcomes in multiple sclerosis patients treated with Tysabri (natalizumab) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Tysabri (Natalizumab)

Snippet

Sponsor: Clinique Neuro-Outaouais | Conditions: Multiple Sclerosis | Status: COMPLETED